

25-OH vitamin D: a predictor of clinical outcomes in primary hyperparathyroidism

Mustafa Sahin¹, Gozde Sengul Aycicek², Demet Çorapçıoğlu¹, Rifat Emral¹, Sevim Güllü¹, Murat Faik Erdogan¹, Vedia Tonyukuk Gedik¹, Nilgun Başkal¹, Ali Rıza Uysal¹

¹Department of Endocrinology and Metabolism, University of Ankara, Turkey,

²Department of Internal Medicine, University of Ankara, Turkey


OBJECTIVES

We aimed to find if there is any relationship between vitamin D levels and clinical, laboratory parameters and osteoporosis, in primary hyperparathyroidism (PHPT).

METHODS

128 patients with PHPT and 30 patients as a control group were analyzed. Patients with PHPT were grouped due to vitamin D levels and levels low than 20 µg/ml accepted as deficiency.

Figure 1: The relation between Metabolic syndrome and T scores.



RESULTS

Patients with 25-OH vitamin D <20 µg/L were younger ($p=0,043$). Also they were more obese; Body mass index (BMI) ≥ 30 ($p=0,18$) and more hypertensive ($p=0,032$). Metabolic syndrome (MS) incidence was higher in the patients with 25-OH vitamin D levels < 20 µg/L. Also, fasting blood glucose, cholesterol levels, triglyceride (TG), glomerular filtration rate (GFR), TSH, free T4, parathormone (PTH), Calcium, 24 hour urinary calcium and neutrophil / lymphocyte ratio were similar. There was no significant difference in the incidence of nephrolithiasis, osteoporosis and parathyroid adenoma size between the groups. Thyroid nodule incidence was 6 times higher in the PHPT. And MS incidence was higher (%32,8) in PHPT ($p=0,042$). 25-OH vitamin D was found to be associated with age, BMI, thyroid volume and triglyceride level in regression analyses. T scores were better in the obese group and in patients with MS.

CONCLUSIONS

25-OH vitamin D levels may be an indicator of hypertension and metabolic syndrome in PHPT. It also may be used as a treatment target in the severe disease. Bone mineral density may not reflect severity in patients with metabolic syndrome.

References

Tran H, Grange JS, Adams-Huet B, Nwariaku FE, Rabaglia JL, Woodruff SL, Holt SA MN. The impact of obesity on the presentation of primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(7):2359–64.

